



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Antonio Portolés**

Organisation/Company: Spanish Agency of Medicines and Medical Devices

Country: Spain

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
07/2020-(current)	Diater	Adrenaline	Anaphylaxia
12/2017-12/2018	Chiesi	beclometasone/formoterol/gli copirronio	Asthma
12/2017-06/2019	Chiesi	topical etofenamate	pain
09/2017-(current)	Farmalider	Analgesics	

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

Classified as public by the European Medicines Agency

Period	Company	Products	Therapeutic Indication
10/2020-03/2022	Kern pharma	ibuprofen	analgesia
10/2020-11/2021	Celltrion	CT59	COVID
06/2017-12/2017	Uriach	Rivaroxaban	anticoagulation
06/2017-(current)	Farmalider	Ibuprofen / acetaminophen or tramadol	analgesia
02/2021-07/2022	Curevac	CNVcov	COVID-19 vaccine
10/2021-(current)	FAES	Metocarbamol	Muscular relaxants

2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2013-12/2013	Tedec-Meiji	Aripiprazole	antipsychotics

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

Period	Products	Therapeutic Indication	Involvement in the repurposing
03/2020-12/2020	Interferon/Hidrocloroquina/Lopinavir	COVID-19 treatment	Involvement in the repurposing of a medicinal product where my organisation is collaborating with the champion of the repurposing

2.10 Any other interests or facts

Member of the Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid.
 Member of the European Association on Clinical Pharmacology and Therapeutics
 National Principal Investigator of a public funding support project for an international clinical trial seeking repositioning of drugs to treat COVID19, sponsored by WHO (Solidarity).

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	ANTONIO PORTOLES
Date:	2022-09-05

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template